BMJ 2005;330 (1 January), doi:10.1136/bmj.330.7481.0-e
Prescribers are increasingly circumvented
What roles do pharmaceutical firms, healthcare organisations, and government regulatory agencies play in switching prescription drugs to over the counter drugs? Cohen and colleagues, prompted by increased numbers of prescription drugs being made available over the counter worldwide, analyse three recent controversial switches: simvastin in the United Kingdom, omeprazole in Sweden, and loratadine in the United States (p 39). They argue that the main motives are pharmaceutical firms' desire to expand their market, attempts to reduce drug bills, and the self care movement.
|
|
Credit: KARL de BLAKER/AP
|
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
StumbleUpon 
Technorati What's this?
Relevant Article
- Switching prescription drugs to over the counter
- Joshua P Cohen, Cherie Paquette, and Catherine P Cairns
BMJ 2005 330: 39-41.[Extract] [Full Text] [PDF]
This Article
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
Related Content
Bookmark with
What's new
Latest blogs
Find BMJ on:
Services
Tools
Online poll
Resources
Rapid responses for this article
There are no rapid responses for this article. Print issues
